Seasonal vaccination with the inactivated influenza vaccine generates antibody profiles that are distinct from those generated by the live-attenuated influenza vaccine Academic Article uri icon


  • Vaccination is an effective strategy for preventing influenza infection and is now recommended annually by the CDC for all individuals age 6 months and above. There are currently two licensed seasonal influenza vaccine formulations in the US: the inactivated influenza vaccine (TIV) and the live-attenuated influenza vaccine (LAIV). A previous clinical trial (FluVacs) conducted in 2007–2008 comparing the efficacy of these two vaccines in adults aged 18–65 reported that both vaccines were efficacious, but the TIV had an overall higher efficacy than the LAIV. We hypothesized that the two vaccines will also generate distinct antibody signatures partially due to the difference in the reported efficacy. We therefore compared the antibody profiles generated by the two vaccines. Profiles were generated using antigen microarrays (AMs) which are a high-throughput binding assay. We generated peptide AMs spotted with overlapping 20mer peptides from a seasonal vaccine strain (2012) and used serum samples of 150 participants from the FluVacs study taken at day 21 post vaccination and at the end of the season. We also used baseline samples to account for previous antibody memory responses. We found that both vaccines generated relatively weak responses when compared to baseline. However, in-line with our hypothesis, the antibody titers generated by the TIV vaccine were higher than those of the LAIV. We then used unsupervised clustering to cluster the post-vaccine responses of all trial participants. We found distinct clusters, each corresponding to a different response pattern. In conclusion we used a novel assay to profile influenza vaccine induced antibody responses and found that the TIV and LAIV vaccines generate different antibody profiles

publication date

  • January 1, 2016